---
title: "A Novel Technology-assisted Home Based Aerobic Exercise Programme for Individuals With Parkinson's Disease"
nct_id: NCT05737316
overall_status: UNKNOWN
phase: NA
sponsor: Tan Tock Seng Hospital
study_type: INTERVENTIONAL
primary_condition: Parkinson Disease
countries: Singapore
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05737316.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05737316"
ct_last_update_post_date: 2023-02-21
last_seen_at: "2026-05-12T06:40:15.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Novel Technology-assisted Home Based Aerobic Exercise Programme for Individuals With Parkinson's Disease

**Official Title:** A Randomised Controlled Feasibility Study of a Novel Technology-assisted Home Based Aerobic Exercise Programme for Individuals With Parkinson's Disease

**NCT ID:** [NCT05737316](https://clinicaltrials.gov/study/NCT05737316)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Tan Tock Seng Hospital
- **Collaborators:** Singhealth Foundation
- **Conditions:** Parkinson Disease
- **Start Date:** 2023-02-11
- **Completion Date:** 2024-06-30
- **CT.gov Last Update:** 2023-02-21

## Brief Summary

This study aim to evaluate the (1) feasibility of a novel mobile application ( Combat PD) that support a home-based gamified aerobic exercise program in individuals with mild Parkinson's disease (PD).

The study aims to further explore (2) the effectiveness of Combat PD in improving adherence to prescribed home-based exercise program; and (3) the clinical effectiveness if combat PD in improving motor and non-motor function in PD.

## Detailed Description

This study aim to evaluate the (1) feasibility of a novel mobile application ( Combat PD) that support a home-based gamified aerobic exercise program in individuals with mild Parkinson's disease (PD).

The study aims to further explore (2) the effectiveness of Combat PD in improving adherence to prescribed home-based exercise program; and (3) the clinical effectiveness if combat PD in improving motor and non-motor function in PD.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Aged 30-75, diagnosed with Parkinson's disease, with mild disease severity (Hoehn and Yahr stages I to II)
2. Sedentary lifestyle
3. Receive a stable dose of dopaminergic medication for at least 4 weeks prior to study inclusion
4. Has a smart phone device

Exclusion Criteria:

1. Uncontrolled hypertension, arrhythmia, or unstable cardiovascular status
2. Poorly controlled diabetes mellitus
3. Advanced kidney disease
4. BMI \> 30
5. Recent cerebrovascular event/ concussion/ fall in the last 6 months
6. Significant cognitive impairment (MoCA\<21)
7. Any other medical/orthopaedic/psychiatric condition that would interfere with ability to participate in the study
8. No stable internet or smart device access
9. Inability to fill up self-reported questionnaires
10. Attendance at any regular exercise programme up to 4 weeks prior to study inclusion
```

## Arms

- **Combat PD** (EXPERIMENTAL) — Combat PD is an aerobic exercise programme hosted on a mobile application.
- **Usual Care** (ACTIVE_COMPARATOR) — Home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises

## Interventions

- **Combat PD** (BEHAVIORAL) — CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
- **Usual Care** (BEHAVIORAL) — Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.

## Primary Outcomes

- **Adherence to exercise program** _(time frame: 12 weeks)_ — actual exercise frequency compared to prescribed exercise targets.
- **Adherence to exercise program** _(time frame: 12 weeks)_ — actual exercise duration compared to prescribed exercise targets.
- **Adherence to exercise program** _(time frame: 12 weeks)_ — actual exercise intensity (period of exercise performed within prescribed heart rate zone), compared to prescribed exercise targets.

## Secondary Outcomes

- **Adverse events** _(time frame: 12 weeks)_
- **Motor section of Movement Disorder Society sponsored Unified Parkinson's disease Rating Scale (MDS-UPDRS-III)** _(time frame: 12 weeks)_
- **Timed Up and Go test (TUG)** _(time frame: 12 weeks)_
- **Dual-task Timed Up and Go Test (TUG)** _(time frame: 12 weeks)_
- **6-minute walk test** _(time frame: 12 weeks)_
- **Montreal Cognitive Assessment (MoCA)** _(time frame: 12 weeks)_
- **Hospital Anxiety and Depression Scale (HADS)** _(time frame: 12 weeks)_
- **Fatigue Severity Scale (FSS)** _(time frame: 12 weeks)_
- **Scales for Outcomes in Parkinson's disease (SCOPA-sleep)** _(time frame: 12 weeks)_
- **Parkinson Disease Questionnaire (PDQ)-8** _(time frame: 12 weeks)_

## Locations (1)

- Tan Tock Seng Hospital, Singapore, Singapore — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tan tock seng hospital|singapore||singapore` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05737316.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05737316*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*